GAITHERSBURG, Md. — December 30, 2025 — Leads & Copy —
BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) today released its annual letter to shareholders, highlighting progress made during 2025 and outlining key priorities and potential catalysts for the year ahead. The company is a technology-enabled drug development company using artificial intelligence (“AI”) and machine learning to enable the successful development of pharmaceuticals and biologics.
According to the letter, 2025 marked an important evolution for BullFrog AI, from platform development and early validation to commercialization and enterprise adoption. The company believes artificial intelligence should augment human expertise, enabling scientists and clinicians to make better, faster, and more confident decisions across the drug discovery and development lifecycle through causal, explainable AI. This philosophy guided the foundational progress made in strengthening technology, validating its real-world relevance, and positioning the Company for what it believes will be a period of rapidly expanding commercial engagement moving forward.
As BullFrog AI enters 2026, the company is engaged in multiple, advanced conversations with global pharmaceutical organizations, relating to potential commercial transactions ranging from out-licensing to discovery research collaborations. These interactions reflect growing recognition of the practical value the company’s platforms can deliver in addressing real drug discovery and development challenges, from data readiness and target discovery to clinical trial optimization, patient stratification, and decision support. Deal structures may include upfront and milestone payments, plus long-term revenue sharing.
In the second quarter of 2025, BullFrog AI entered into a commercial collaboration with Sygnature Discovery, a contract research organization, that is expected to generate revenue through 2028. Sygnature’s global business development team is now actively introducing BullFrog Data Networks™ to its biopharma client base. This collaboration provides an efficient pathway to scale adoption of BullFrog AI’s platform while requiring limited incremental investment.
BullFrog AI expanded its internal sales and marketing efforts to directly support clinical trial optimization solutions, including bfPREP™, its proprietary data preparation tool. The team is increasingly leveraging demonstrable platform successes, including validated oncology and neuroscience use cases, to drive deeper engagement across prospects in oncology, neuroscience, and rare disease.
The company says a major achievement this year was the continued evolution of its technology into a modular, enterprise-grade solutions stack designed to support broader commercial adoption. The launch of BullFrog Data Networks™ and the accompanying solutions library represents a meaningful advancement in how large biopharma organizations can deploy technology within existing infrastructure and workflows. The platform supports native deployment across all major cloud environments and allows clients to adopt targeted solution modules or expand into multi-module, end-to-end engagements over time.
BullFrog AI’s collaboration with Eleison Pharmaceuticals represents the first, substantive real-world deployment of BullFrog AI’s platforms within a late-stage oncology development program. Working alongside Eleison’s clinical development team, BullFrog AI applied its proprietary technology to complex historical, clinical trial data to support patient stratification, trial optimization, and decision-making in a pivotal Phase 3 setting.
Insights generated through this collaboration were showcased in a jointly authored abstract that was accepted for presentation at the 2026 ASCO Gastrointestinal Cancers Symposium, a highly respected oncology forum. Once disclosed at ASCO on January 9, 2026, the findings will provide BullFrog AI’s internal sales team, as well as Sygnature Discovery, with a proof point that can help advance active discussions and strengthen future commercial engagement with pharmaceutical companies evaluating the company’s technology.
One of the most strategically important developments of the year was the launch of bfPREP™, BullFrog AI’s AI-powered data preparation and standardization module. By automating data cleansing, normalization, and transformation, bfPREP™ can reduce data preparation timelines from months to days and integrates seamlessly into downstream analytics workflows.
Throughout the year, BullFrog AI maintained a disciplined approach to capital allocation while continuing to invest selectively in areas that support commercialization and platform scalability. BullFrog AI operates with a lean cost structure, with an annual burn of approximately $6.2 million.
In the year ahead, BullFrog AI expects several developments to serve as important catalysts, including continued commercialization through Sygnature Discovery, expanding direct engagement around bfPREP™ and clinical trial optimization solutions, the public presentation of its Eleison collaboration data at ASCO in January, and executing contracts and partnerships with large pharmaceutical companies that leverage its entire platform, data and know-how.
Vin Singh, Founder and Chief Executive Officer of BullFrog AI Holdings, Inc., thanked shareholders for their continued confidence and support.
Investor Relations Contact:
Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
BFRG@redchip.com
Public Relations Contact:
pr@bullfrogai.com
Source: BullFrog AI
